Literature DB >> 26632865

Targeted Metabolomics Approach To Detect the Misuse of Steroidal Aromatase Inhibitors in Equine Sports by Biomarker Profiling.

George Ho Man Chan1, Emmie Ngai Man Ho1, David Kwan Kon Leung1, Kin Sing Wong1, Terence See Ming Wan1.   

Abstract

The use of anabolic androgenic steroids (AAS) is prohibited in both human and equine sports. The conventional approach in doping control testing for AAS (as well as other prohibited substances) is accomplished by the direct detection of target AAS or their characteristic metabolites in biological samples using hyphenated techniques such as gas chromatography or liquid chromatography coupled with mass spectrometry. Such an approach, however, falls short when dealing with unknown designer steroids where reference materials and their pharmacokinetics are not available. In addition, AASs with fast elimination times render the direct detection approach ineffective as the detection window is short. A targeted metabolomics approach is a plausible alternative to the conventional direct detection approach for controlling the misuse of AAS in sports. Because the administration of AAS of the same class may trigger similar physiological responses or effects in the body, it may be possible to detect such administrations by monitoring changes in the endogenous steroidal expression profile. This study attempts to evaluate the viability of using the targeted metabolomics approach to detect the administration of steroidal aromatase inhibitors, namely androst-4-ene-3,6,17-trione (6-OXO) and androsta-1,4,6-triene-3,17-dione (ATD), in horses. Total (free and conjugated) urinary concentrations of 31 endogenous steroids were determined by gas chromatography-tandem mass spectrometry for a group of 2 resting and 2 in-training thoroughbred geldings treated with either 6-OXO or ATD. Similar data were also obtained from a control (untreated) group of in-training thoroughbred geldings (n = 28). Statistical processing and chemometric procedures using principle component analysis and orthogonal projection to latent structures-discriminant analysis (OPLS-DA) have highlighted 7 potential biomarkers that could be used to differentiate urine samples obtained from the control and the treated groups. On the basis of this targeted metabolomic approach, the administration of 6-OXO and ATD could be detected for much longer relative to that of the conventional direct detection approach.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26632865     DOI: 10.1021/acs.analchem.5b03165

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  5 in total

1.  Novel Chemical Ligands to Ebola Virus and Marburg Virus Nucleoproteins Identified by Combining Affinity Mass Spectrometry and Metabolomics Approaches.

Authors:  Xu Fu; Zhihua Wang; Lixin Li; Shishang Dong; Zhucui Li; Zhenzuo Jiang; Yuefei Wang; Wenqing Shui
Journal:  Sci Rep       Date:  2016-07-12       Impact factor: 4.379

2.  Metabolomics approach by 1H NMR spectroscopy of serum reveals progression axes for asymptomatic hyperuricemia and gout.

Authors:  Yannan Zhang; Huanzhen Zhang; Dong Chang; Fuchuan Guo; Hongzhi Pan; Yuexin Yang
Journal:  Arthritis Res Ther       Date:  2018-06-05       Impact factor: 5.156

3.  Plasma Metabolic Profiling Analysis of Gout Party on Acute Gout Arthritis Rats Based on UHPLC-Q-TOF/MS Combined with Multivariate Statistical Analysis.

Authors:  Yuming Wang; Chenghao Bi; Wentao Pang; Yuechen Liu; Yu Yuan; Huan Zhao; Tianpu Zhang; Yungang Zhao; Yubo Li
Journal:  Int J Mol Sci       Date:  2019-11-15       Impact factor: 5.923

Review 4.  Metabolomics in clinical and forensic toxicology, sports anti-doping and veterinary residues.

Authors:  Bethany Keen; Adam Cawley; Brian Reedy; Shanlin Fu
Journal:  Drug Test Anal       Date:  2022-03-08       Impact factor: 3.234

5.  Serial-omics characterization of equine urine.

Authors:  Min Yuan; Susanne B Breitkopf; John M Asara
Journal:  PLoS One       Date:  2017-10-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.